

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 8-K

**CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **October 25, 2021**

ACCURAY INCORPORATED

(Exact name of registrant as specified in charter)

Delaware

(State or other jurisdiction of incorporation)

001-33301
(Commission File Number)

20-8370041
(IRS Employer Identification No.)

**1310 Chesapeake Terrace
Sunnyvale, California 94089**
(Address of principal executive offices, including Zip Code)

Registrant's telephone number, including area code: **(408) 716-4600**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.001 per share	ARAY	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 7.01. Regulation FD Disclosure.

On October 25, 2021, Accuray Incorporated (the “Company”) will be hosting an Analyst & Investor Meeting (the “Investor Meeting”) in conjunction with the American Society of Radiation Oncology (ASTRO) Annual Meeting. The Investor Meeting will take place in person at the ASTRO meeting and on a virtual platform, with presentations beginning 3:00pm CT (4:00pm ET). A replay of the Investor Meeting will be available on the investor relations portion of the Company’s website following the event.

At the Investor Meeting, management intends to present the management presentation slides attached hereto as Exhibit 99.1 to discuss, among other things, the Company’s technologies and long-term business and growth strategies. The management presentation slides will also be posted on the investor relations portion of the Company’s website.

The information contained in this Current Report on Form 8-K, including Exhibit 99.1, is furnished pursuant to Item 7.01 and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be incorporated by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

<u>Exhibit No.</u>	<u>Description</u>
99.1	Management Presentation Slides of Accuray Incorporated dated October 25, 2021.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

ACCURAY


Accuray
Overview
Video



ACCURAY

Accuray Transforming Patient Care Through Innovation

Investor Day



October 25, 2021



01	Welcome Ken Mobeck VP, FP&A and Investor Relations		
02	Overview Josh Levine Chief Executive Officer		
03	Long Term Growth Catalysts Suzanne Winter President		
04	Clinical Evidence Jean-Philippe Pignol SVP, Chief Medical & Technology Officer		
		The Accuray Product Difference Corey Lawson VP, Product Strategy	05
		Financials Brandy Green Interim Chief Financial Officer	06
		Closing Josh Levine Chief Executive Officer	07
		Q & A	08

Forward-looking statements

**This presentation is intended exclusively for
investors.**

It is not intended for use in Sales or Marketing

Safe Harbor Statement

Statements in this presentation (including the oral commentary that accompanies it) that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this presentation relate, but are not limited, to: our preliminary financial results, including expectations regarding gross orders, revenues and adjusted EBITDA for the first quarter of fiscal 2022; expectations regarding fiscal 2022 full-year adjusted EBITDA and revenue; our positioning and strategy for accelerating revenue, market share and margin expansion, including expectations regarding our financial model; expectations regarding market growth rates and market trends; expectations regarding new product enhancements or offerings; expectations regarding partnerships and planned partnerships; our long term growth catalysts; expectations related to our joint-venture in China and Type-B product, including our ability to drive additional growth and market share in China; our ability to expand addressable markets; and our ability to capitalize on operating leverage to drive greater profits and cash flows. Forward-looking statements generally can be identified by words such as "anticipates," "believes," "estimates," "expects," "intends," "plans," "projects," "may," "will be," "will continue," and similar expressions. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from expectations. These risks and uncertainties include, but are not limited to: the effects of the COVID-19 pandemic on our business, financial condition, results of operations or cash flows; our ability to achieve widespread market acceptance of our products, including new product offerings and improvements; our ability to develop new products or enhance existing products to meet customers' needs and compete favorably in the market; our ability to realize the expected benefits of the joint-venture and other partnerships; risks inherent in international operations; our ability to effectively manage our growth; our ability to maintain or increase our gross margins on product sales and services; delays in regulatory approvals or the development or release of new offerings; our ability to meet the covenants under our credit facilities; our ability to convert backlog to revenue; and other risks identified under the heading "Risk Factors" in our annual report on Form 10-K, filed with the Securities and Exchange Commission (the "SEC") on August 17, 2021, and as updated periodically with our other filings with the SEC.

Forward-looking statements speak only as of the date the statements are made and are based on information available to Accuray at the time those statements are made and/or management's good faith belief as of that time with respect to future events. Accuray assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not place undue reliance on any forward-looking statements.

Non-GAAP Financial Measures

This presentation also contains non-GAAP financial measures. Management believes that non-GAAP financial measures provide useful supplemental information to management and investors regarding the performance of the company and facilitates a more meaningful comparison of results for current periods with previous operating results. Additionally, these non-GAAP financial measures assist management in analyzing future trends, making strategic and business decisions, and establishing internal budgets and forecasts. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP measure is provided in the Appendix.

There are limitations in using these non-GAAP financial measures because they are not prepared in accordance with GAAP and may be different from non-GAAP financial measures used by other companies. These non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial measures. Investors and potential investors should consider non-GAAP financial measures only in conjunction with the company's consolidated financial statements prepared in accordance with GAAP.

Medical Advice Disclaimer

Accuray Incorporated as a medical device manufacturer cannot and does not recommend specific treatment approaches. Individual results may vary.

Our Vision:
 To **EXPAND** the
CURATIVE
POWER of
RADIATION
THERAPY to
 improve as many
 lives as possible



- Broader treatment options
- Beyond oncology
- Global patient access



- Precision technology
- Superior patient experience
- Partnerships



- Enable advanced treatments
- Survival, long term outcomes
- Quality of life



- Focused resources
- Expertise
- Best in class

Entering the Golden Age of Radiotherapy

ACCURAY

Accuray is leading the transformation

1 Versus 8
Week
Treatments*

Imaging
Innovation

Adaptive
Therapy

Partnerships

Drug/Device
Combination

*SBRT treatments vs conventional fractionated treatments (5 sessions vs 35 to 40 sessions)

Radixact® System TomoTherapy® System	CyberKnife® S7™ System	Accuray Precision® Treatment Planning System
		
Ultimate IMRT/SBRT Workhorse	Dedicated Whole Body SRS/SBRT System	Connectivity to the RT Department
Personalized Universal Fast	4D Dynamic Delivery Precise Speed	Efficient Integrated Automated

Strategy for Accelerating Revenue and Margin

Financial model designed to both invest as well as grow the top line

Reposition for Success

FY18 - FY19

- Enhanced leadership
- Established China JV
- Introduced Synchrony®
- Improved cost structure and operating leverage

Transform Culture and Begin Innovation Driven Growth

FY20 - FY21

- Redefined vision and technology roadmap
- China type-A revenue ramp
- Build our global infrastructure and operations
- Restructured debt for growth

Accelerate Growth

FY22+ Plan

- New products and partnerships
- Execution on China growth
- Expand markets and drive market share gain
- Drive greater profits and cash flows

Long Term Growth Catalysts


Commercial Orders Momentum Entering FY22

Four (4) Accuray business regions and strategies

ACCURAY
+19% Q4 Y/Y^a
+39% Q1 Y/Y^b

WW MARKET
+4.2%^c

CAGR 2021-2026





Technology Innovation Pipeline



China Growth and Unique Business Model



New Market Opportunities



Acceleration of Favorable Market Trends

Robust Technology Pipeline

ACCURAY




15%
of Revenue
Invested
in **R&D***

Versatility – Connectivity – Speed – Quality

*R&D as a planned percentage of revenue FY22

China Growth and Unique Business Model

- 175 employees
- Commercial execution:
 - Type-A: 85% market share*
 - Type-B: Commercial coverage with JV product on-track
- Customer support team active with 30 systems installed in calendar 2021
- World class training and education center



*100 out of 118 type-A licenses awarded in the 13th - 5-year plan

Proprietary and Confidential Property of Accuray

JV Manufacturing Facility Prepared for Type-B Product



China JV
manufacturing
ready for
BIMT^a testing

- ISO 13485 certified
- Type-B product on track
 - Planned market introduction in summer 2022
 - Anticipate shipments following NMPA^b approval by end of CY2022
- Sister manufacturing site development

15

^a BIMT: China Medical Manufacturer, Diagnostic, Testing supplier

^b NMPA: The National Medical Products Administration (NMPA) is the Chinese agency for regulating drugs and medical devices (formerly the China Food and Drug Administration or CFDA)

Proprietary and Confidential Property of Accuray



New Market Opportunities

Expansion to Global Value Segment

Target emerging markets where RT is underpenetrated

ACCURAY

Expand Patient Access

Reduced Total Cost of Care

Workflow Efficiency

Upgradeability Path

High Throughput and Quality

Differentiated Feature Set

Base Clinical Capabilities with Options

Mid-CY2023 Availability



\$300M Annual Opportunity*

* Internal total new unit market forecast FY23 (Brazil and India)

NeuroRadiosurgery: Replacement Market Opportunity

CyberKnife® S7™ Neuro Package with Brainlab®



- Target neurosurgeons
- Treats brain AND spine
- Improved patient experience
- Synchrony® 4D dynamic delivery
- No cobalt source



\$600M aged Gamma Knife® opportunity through 2026*

*MarketsAndMarkets RADIOTHERAPY MARKET - GLOBAL FORECAST TO 2026
Gamma Knife is a registered trademark of Elekta AB (publ)

Proprietary and Confidential Property of Accuray



**Dr. DAVID
ROBERGE**

Adjunct Professor,
Oncology
McGill University,
CHUM - Notre
Dame



Market Trends and Technology Implications

Growing Use of Ultra-Hypofractionated Treatments

Ultra-Hypofractionation (SRS/SBRT)*



21

*Medicare is subset of total treatments
2015 - 2019 Medicare Hospital Outpatient Standards Analytics File; 2015 - 2018 The Medicare Physician & Other Practitioners by Provider and Service dataset Public Use File; Freestanding volume for 2019 estimated based on annual 2015-2018 average growth rates

Proprietary and Confidential Property of Accuray

COVID-19: Accelerates Hypofractionation Adoption

Guidelines

ASTRO

ESTRO

DEGRO

NICE

Australia
New
Zealand



Reduce the patient and provider risk of exposure

Increasing Clinical Evidence

Breast Cancer

- NASPB-B39, RAPID, Florence Trial

Prostate Cancer

- CHHIP, HYPRO, PACE-B

Lung Cancer

- ROSEL, RTOG 0915

Brain Metastases

- JROSG 99-1, NCT00377156

Bone Metastases


- RTOG 97-14, NCT00080912

Oligometastases

- COMET, NCT01725165


Aged Equipment Need Technology Upgrade

40% U.S. Installed Base >9 years^a



- Installed base is aged
- Technology needed for ultra-HF treatments
- Increase annual patients treated
- Compete more effectively in RO-APM reimbursement
- Potential for improved outcomes and quality of life

Treat More Patients with Ultra-Hypofractionation^b



^a IMV 2019 Radiation Therapy Market Summary Report
^b Accuray internal data on file

Proprietary and Confidential Property of Accuray



**PROF.
RAPHAEL
MOECKLI**

Group Leader,
Medical Physicist
at CHUV

Positioned to Win in Value Based Care

ACCURAY

Deliver more.
Better. Faster.

CYBERKNIFE® S7™

System

- Global leader in SRS/SBRT
- Only robotic delivery system
- Fast <15 min treatments



RADIXACT® System

- 360-degree helical arc therapy
- IMRT and SBRT
- Fast <15 min treatments



ACCURAY-ONLY TECHNOLOGY

- Outstanding image quality
- Synchrony® 4D dynamic delivery
- VOLO™ and VOLO Ultra speed
- Patient experience



Synchrony®




ClearRT™



VOLO™



Clinical Evidence



PACE-B Prostate Study Shows Lower Side Effects with the CyberKnife® System

ACCURAY

Study shows 50% less bladder side effects compared to conventional linac



50% less bladder side effects^c

- ~ 1 in 8 men in the U.S. will be diagnosed with prostate cancer^a
- First phase 3 trial testing 5-fraction SBRT for prostate^b
- N=874 patients from 37 centers in 3 countries^b
- Subset analysis of the SBRT arm is favorable for the CyberKnife system

^a American Cancer Society

^b Dr. Alison Tree, Royal Marsden Hospital, London, UK: Oral presentation and book of abstract at ESTRO 2021, Madrid, Spain

^c Compared to conventional linac. Dr. Alison Tree, Royal Marsden Hospital, London, UK: Oral presentation at ESTRO 2021, Madrid, Spain




Dr. ALISON TREE
Consultant Clinical
Oncologist at The Royal
Marsden NHS
Foundation Trust

Accelerated Partial Breast Irradiation Delivered with the CyberKnife® System

ACCURAY

Study shows a lower secondary lung cancer risk compared to conventional linac



Up to 85% reduction of this risk using CyberKnife® System^c

- ~ 1 in 8 women in the U.S. will develop invasive breast cancer^a
- 80% of all breast cancer treated are early stage, outcomes are excellent^b
- Retrospective analysis and modeling of long-term risk of dying of secondary lung cancer

^a BreastCancer.org
^b American Cancer Society: Cancer Facts and Figures 2021
^c Pignol et al. Front. Oncol. 11:713328

Proprietary and Confidential Property of Accuray

Head and Neck Cancer Delivered on the TomoTherapy® System

ACCURAY

Study shows lower salivary toxicity compared with conventional linac



Lower salivary side effects for TomoTherapy® patients^a (7.5% vs. 20.4% with conventional linac)

- 1 in 50 people affected by head and neck cancer^b
- High mortality rate^c
- N=166 patients with head and neck cancer, from 14 centers^a
- TomoTherapy® compared with conventional linac showed better tumor control and specific survival^a

^a Bibault JE, et al. (2017) International Journal of Radiation Oncology * Biology * Physics
^b American Cancer Society. Cancer Facts and Figures 2021
^c SEER database

Proprietary and Confidential Property of Accuray

Pancreatic Cancer: Combination with

Study shows increasing overall survival for locally recurrent cancer compared to SBRT with chemotherapy



Improved overall and progression-free survivals with SBRT plus immunotherapy^a

- Pancreatic cancer survival is low, about 11%^b
- N=170 patients randomized to CyberKnife[®] System SBRT plus immunotherapy vs. chemotherapy^a
- Excellent patient tolerance^a

^a Zhu X., Cao Y., Liu W., et al. The Lancet Oncology, Volume 22, Issue 8, 2021, Pages 1093-110.
^b SEER database

Our Vision:

Expand the curative power of radiation therapy to improve as many lives as possible

ACCURAY

Surgical Precision

Non-Invasive

Comfortable

Fast

Enable Improved Outcomes

Enable Quality of Life



HOPE



The Accuray Product Difference



Radixact® System

The Ultimate
Full-body,
Workhorse Radiation
Therapy Device



**Radixact®
System**

The Radixact[®] System: a Universal Workhorse

ACCURAY

**Unique
Helical
Platform**

Simple
VOLO[™] Ultra
Planning

Precise Helical
Dose Painting

Synchrony[®]
4D Tumor
Tracking w/
Dynamic
Delivery

**Any Case
Complexity**

Diagnostic-
like ClearRT[™]
Imaging

Quick
Installation

Vendor
Neutral
Connectivity



Proprietary and Confidential Property of Accuray


ClearRT™ Helical kVCT Imaging

Radixact® System's unique helical platform advantages




ADVANTAGES



- Diagnostic-like quality
- Largest field of view (FOV) and scan length
- Fast 1-meter in 1-minute
- Upgradeable into the IB



ClearRT™




Planning



The Competition

Conebeam CT comparison

Conebeam CT



Slow

- Elekta OBI: ~ 60-120 sec
- Varian TrueBeam®: ~ 33-60 sec
- Varian Halcyon™: ~ 17-40 sec

Artifacts

- Non-uniformity
- Geometric distortion

Limited Field of View

- ~ 20 cm maximum scan length
- <15 cm reduced artifact

Photo from "Domain adversarial networks and intensity-based data augmentation for male pelvic organ segmentation in cone beam CT" by Elliott Brion, Jean Leger, A.M. Barragan-Montero, Nicolas Meert, John A. Lee, and Benoit Macq / CC BY4.0 / Arrows added for emphasis

38 Elekta is a registered trademark of Elekta AB. Varian, TrueBeam, and Halcyon are trademarks or registered trademarks of Varian Medical Systems, Inc.

Proprietary and Confidential Property of Accuray

The Competition

ACCURAY

Comparing to typical MR-Linac and conebeam CT

■ Excellent
 ■ Good
 ■ Poor

	ClearRT™ Imaging	MR-Linac	Conebeam CT
Scan Speed – 20 cm (Typical)	20 sec ■	60 sec – 180 sec ■	30 sec – 75 sec ■
Axial Scan Length Max (Typical)	135 cm ■	43 cm ■	20 cm ■
Transverse FOV Max (Typical)	50 cm ■	35 cm ■	40 cm ■
Uniformity	Excellent ■	Good ■	Poor ■
Contrast Resolution	Good ■	Excellent ■	Poor ■
Spatial Integrity	Excellent ■	Poor ■	Good ■
Motion Delivery	Synchrony – X-ray ■	Gating – MR ■	Gating – X-ray ■
Density Accuracy (Adaptive)	Yes – Diagnostic like ■	None ■	NA – Plan image fusion ■
System Price (Typical)	\$ ■	\$\$\$\$ ■	\$ ■
Service Price (Typical)	\$ ■	\$\$\$ ■	\$ ■




Dr. LANE ROSEN
Willis-Knighton

Clinical Challenge

Targets move - Life is always in motion

ACCURAY



Methods of correcting for breathing, circulation, and digestion



Expand treatment margins and treat the entire motion envelope - ITV



Manage breathing, and turn the beam ON/OFF depending on tumor position - gating



Efficiently follow the dynamically moving target with the beam - **Accuray Synchrony®** motion tracking

Compensating for Movement

Technique matters



ITV (internal target volume)
healthy tissue receives a majority of the radiation dose

- Enables dose escalation to the target
- Decreases radiation to healthy surrounding tissue
- Potentially helps clinicians positively impact patient outcomes



Synchrony[®]
cancerous tissue receives a majority of the radiation dose

Managing Breathing

ACCURAY

Accuray does NOT require restrictive devices

Patient Restraint:
Abdominal Compression



Trained Breathing Device:
Enable Predictable Gating



1 of 3 Patients Typically Unable to Tolerate*

Synchrony® 4D Motion Tracking with Dynamic

Efficient and precise, comfortable for the patient




Minimize Margins: Potential for improved outcomes, and enables ultra-hypofractionation



Deliver Efficiently: Treat more patients, at lower cost, with overall higher profitability




Breath Naturally: Greater patient comfort, and a better experience



Partnership with C-RAD

Protect the heart
Focus beam on the
tumor/tumor bed

- **Non-ionizing optical imaging** patient setup
- **Automated pause/resume** specific to the needs of treating breast cancer patients



C-RAD Catalyst+ HD



**Dr. ANAND
MAHADEVAN**

Professor and
Chairman of
Radiation
Oncology at
Geisinger
Health System



CyberKnife® System

Dedicated Whole Body
SRS/SBRT System



**CyberKnife®
System**

The CyberKnife® Radiosurgery System

ACCURAY

**Unique
Robotic
Platform**

Submillimeter
Accuracy

Thousands of
Beam Angles

Fast Delivery

**Versatile
SRS/SBRT
System**

Flexible
Collimation
For Various
Cases

Powerful
Planning
Choices

Moving Or
Stationary
Targets



Proprietary and Confidential Property of Accuray

The CyberKnife® System with RayStation® Planning

ACCURAY

RaySearch
Laboratories

Partnership with
RaySearch

 RayCare®



iDMS®
Data
Management
System



 RayStation®



- Latest generation RaySearch plan optimizer
- Protocols and scripting automation tools
- RayPhysics® enables seamless machine commissioning
- Highly intuitive workflows for which RayStation® is known

*RayStation® and RayCare®: subject to regulatory clearance in some markets

Proprietary and Confidential Property of Accuray

CyberKnife® Neuro Radiosurgery System

Planned Partnership with Brainlab®



Elements Neuro Pre-planning, and Qentry®
Familiar to neurosurgeons;
Supports clinical evidence
generation via registry access

Frameless and Frame Option*
Expands treatment to
functional disease



Brain AND Spine Treatments


Oligometastatic Treatments
Improves efficiency in treating
multiple brain metastases

Collimation
Tailors to common
neurosurgical case demands



**Dr. ADITYA
GUPTA**

**Chief Neurosurgeon
at Artemis Hospital**



- Closed a historical gap
- Seamless workflow: scheduling, image review, treatment capture
- Electronic medical record integration ensures a complete patient record
- Everyone wins: IHE-RO industry consortium's commitment to expanding development, and testing

Accuray Systems Have Vendor-Neutral OIS Connectivity

Innovation Continues

ClearRT™ Imaging Critical Input to Adaptive Workflow

1 Plan and enroll

- Accuray Precision®
- Partnership with RaySearch

1



2 Acquire daily image

- ClearRT™
- True helical CT
- Diagnostic-like image quality

2

3 Calculate planned dose on daily image

- Rethinking the workflow

3

Determine key radiomics inputs

4 Deform the contours on daily image

- Applied intelligence

4

5 Accumulate dose over the course of treatment

- Quality assurance

5

6 Review and decide

- Clinical decisions

6



Immunotherapy with RT
for abscopal effect



Automation "one-stop-shop"
and daily adaptive RT



The future of the CyberKnife®
system beyond 3D imaging



KOL THINK TANKS

Financial Update

Key Financial Metrics^a

ACCURAY

ACTUALS

PRE-ANNOUNCEMENT

Q4 FY21
Y/Y

FY21
Y/Y

Q1 FY22
Y/Y^b

	Q4 FY21 Y/Y	FY21 Y/Y	Q1 FY22 Y/Y ^b
Gross orders	\$113M 19%	\$326M (14%)	\$70M 39%
Revenues	\$111M 17%	\$396M 3%	\$107M 26%
Product	\$56M 39%	\$177M 6%	-
Service	\$55M 0%	\$220M 2%	-
Op. Expenses	\$39.6M 15%	\$137.2M 0.1%	-
R&D	\$15.4M 26%	\$52.7M 6%	-
SG&A	\$24.2M 9%	\$84.5M (3%)	-
Adj. EBITDA^c	\$6.7M (33%)	\$38M 38%	\$4.5M-\$5.5M (50%)^d



Q1 FY22

HIGHLIGHTS

- New product innovation driving order momentum
- Largest fiscal first quarter revenue number in Company history
- Raised FY22 full year revenue guidance to \$420M to \$427M
- Tightened FY22 full year adjusted EBITDA to the range of \$33M to \$35M^c

^a FY22 revenue guidance as presented in press release dated October 21, 2021. This presentation should not be construed as a reaffirmation of such guidance.

^b Represents preliminary unaudited financial results announced in press release dated October 21, 2021. Actual results may vary.

^c Adjusted EBITDA is a non-GAAP measure. Please see Appendix for a reconciliation of adjusted EBITDA to the most directly comparable GAAP measure.

^d Value is the midpoint of the range.

Proprietary and Confidential Property of Accuray

Improved Q4 FY21 Balance Sheet for Future

Key parameters are strengthening based on actions taken

ACCURAY



Strategy for Accelerating Revenue and Margin Expansion

Financial model designed to both invest as well as grow the top line

Reposition for Success

FY18 - FY19

- Enhanced leadership team
- Established China joint-venture
- Introduced Synchrony
- **Reset cost structure to increase operating leverage**

Transform Culture and Begin Innovation Driven Growth

FY20 - FY21

- Redefined vision and strategic roadmap
- High impact product introduction
- Executed China type-A revenue ramp
- **Continued to build out our global infrastructure and operations**
- **Restructured debt to allow for growth**

Accelerate Growth

FY22+ Plan

- Consistent cadence of new products and partnerships
- Drive additional growth and share in China market
- Expand addressable markets and drive further market share gain
- **Capitalize on operating leverage to drive greater profits and cash flows**

Closing Remarks



Entering FY22 With
Accelerating Momentum



Strongest Product Portfolio and
Pipeline in Company's History



Multiple Growth Catalysts and
Global Commercial Execution



Strengthened Leadership Team
and Operational Foundation

Positioned for
**Accelerated
Revenue
Growth, Market
Share Gains
and Margin
Expansion**



Q&A

Thank you



Appendix

GAAP to Adjusted EBITDA FY21

Actual Reconciliation of Net Income (Loss) to Adjusted Earnings Before Interest, Taxes, Depreciation, Amortization and Stock-Based Compensation (Adjusted EBITDA)

ACCURAY

\$k	Three Months Ended June 30		Twelve Months Ended June 30	
	2021	2020	2021	2020
GAAP net income (loss)	\$ (11,092)	\$ (152)	\$ (6,311)	\$ 3,827
Depreciation and amortization	1,498	1,960	6,389	7,526
Stock-based compensation	2,236	2,287	9,332	8,152
Interest expense, net	3,734	4,590	16,877	17,986
One-time charge related to debt refinance and convertible exchange (a)	9,948	—	9,948	—
Gain on contribution to equity method investment in joint-venture (b)	—	—	—	(12,965)
Cost savings initiative (c)	—	1,058	—	1,058
Provision for income taxes	400	262	1,752	1,863
Adjusted EBITDA	\$ 6,724	\$ 10,005	\$ 37,987	\$ 27,447

(a) consists of one-time charge related to the exchange of our 3.75% Convertible Senior Notes due July 2022 for our new 3.75% Convertible Senior Notes due May 2026 and the refinancing of our senior secured revolving credit facility and term loan with new lenders.

(b) consists of non-cash gain related to the value of the Company's capital contribution to the China joint venture.

(c) consists of costs associated with reduction of staff.

GAAP to Adjusted EBITDA Q1 Preliminary and FY22 Projected Guidance

ACCURAY

Projected Guidance Reconciliation of Net Income (Loss) to Adjusted Earnings Before Interest, Taxes, Depreciation, Amortization and Stock-Based Compensation (Adjusted EBITDA)

SK	Preliminary Three Months Ended September 30, 2021				Twelve Months Ended Projection for June 30, 2022			
	Low		High		Low		High	
GAAP net income (loss)	\$	(2,000)	\$	(1,000)	\$	4,900	\$	6,600
Depreciation and amortization		1,500		1,500		6,500		6,500
Stock-based compensation		2,500		2,500		10,900		10,900
Interest expense, net		2,100		2,100		8,300		8,300
Provision for income taxes		400		400		2,400		2,700
Adjusted EBITDA	\$	4,500	\$	5,500	\$	33,000	\$	35,000

GAAP to Adjusted EBITDA FY19

Actual Reconciliation of Net Income (Loss) to Adjusted Earnings Before Interest, Taxes, Depreciation, Amortization and Stock-Based Compensation (Adjusted EBITDA)

ACCURAY

\$K	Three Months Ended June 30	Twelve Months Ended June 30
	2019	2019
GAAP net income (loss)	\$ (1,400)	\$ (16,430)
Depreciation and amortization	2,178	8,266
Stock-based compensation	2,822	10,601
Interest expense, net	3,973	15,015
Impairment charge (a)	—	3,707
Cost savings initiative (b)	511	1,509
Gain on lease termination (c)		(1,007)
Provision for income taxes	864	2,086
Adjusted EBITDA	\$ 8,948	\$ 23,747

(a) consists of an accounts receivable impairment charge related to one customer in the first quarter of 2019

(b) consists of costs associated with reduction of staff

(c) consists of a non-cash reversal of deferred rent related to a facility lease that was terminated

